N-Methyl-PPPA explained

N-Methyl-PPPA, or N-methyl-3-phenoxy-3-phenylpropan-1-amine, is a serotonin-norepinephrine reuptake inhibitor (SNRI) which was developed by Eli Lilly from diphenhydramine in the early 1970s while in search of new antidepressants, but was never marketed.^{[1] [2] [3]} It is closely related structurally to fluoxetine, atomoxetine, and nisoxetine.

See also

• 3-Phenoxy-3-phenylpropan-1-amine (PPPA)
• Development and discovery of SSRI drugs
• Aryloxypropanamine scaffold

Notes and References

1. Book: López-Muñoz F, Álamo C . Contribution of Pharmacology to Development of Monoaminergic Hypothesis . Lopez-Munoz F, Alamo C . Neurobiology of Depression. https://books.google.com/books?id=lmXRBQAAQBAJ&pg=PA132. 9 September 2011. CRC Press. 978-1-4398-3850-1. 132–.
2. Book: Sneader W . Drugs Originating from the Screening of Organic Chemicals . Drug Discovery: A History. https://books.google.com/books?id=jglFsz5EJR8C&pg=PA416. 31 October 2005. John Wiley & Sons. 978-0-470-01552-0. 416–417 . 10.1002/0470015535.ch28 .
3. Wong DT, Bymaster FP, Engleman EA . Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication . Life Sciences . 57 . 5 . 411–441 . 1995 . 7623609 . 10.1016/0024-3205(95)00209-o .